⚠️ Uptrend Under Pressure Severe risk · 99 · Institutional selling is building — 6 distribution days in the last 25 sessions. · 6 distribution days (SPY) Full briefing → Jul 28
Simple research view

DXCM · DexCom, Inc.

$73.37 latest stored close
Detected setup Wyckoff SOS

Watch · Quality 22/100

Ask about DXCM

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

Scans / Health Technology / DXCM

$DXCM

DexCom, Inc.

DexCom, Inc. is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $28B.

Buy · 67 Health Technology Medical Specialties stock Stage 2 · Advancing Base 3+ Data 59m ago
$73.37 latest close
Council read · 6 methods

Watch — evidence is building

0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.

Earnings-risk mode

Pre-earnings setup

Wednesday, July 29, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

DXCM+2.56%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
Same completed session window ending 2026-07-27. DXCM was +2.05 points vs XLV. +2.54 points vs SPY.
CatalystUnavailable Stock reactionPositive Sector reactionSupportive Opening surgeUnavailable Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.
Price $73.37 Jul 27 close
52W High $89.98 -18.5%
52W Low $54.11
Wks Since High 49w
Base Depth -39.9%
Base B3
SMA 50 $72.00
SMA 200 $67.54
Avg Vol 5,632,725
RS Rank 11
RS vs High -29.4%
RS Slope +5.1% ▲
Grp Rank #48/64
ADR% 3.5%
ATR(14) $2.79 (3.8%)
Rel Vol (today) 0.89×
Vol Pace N/A
U/D Vol 1.14
A/D Days 16A / 5D
A/D Rating A+
VDU Bars 0/10 d
Power Trend 1d
Earnings tmrw
$54.11
$89.98 54%

DXCM Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for DXCM.

Create Free Account
Setup Quality B 4/7 signals
Jul 22: 61 (Trend Only)Jul 23: 49 (Trend Only)Jul 27: 0 (watchlist_candidate)Jul 28: 49 (Wyckoff SOS)Jul 28: 49 (Wyckoff SOS)49 Score trend
✓ Stage 2 · Advancing ✗ Power Trend 1d ✗ RS New High ✓ Trend 7/8 ✗ No Pattern ✓ CANSLIM 62.4 (C) ✓ Gatekeeper Base #3 (C)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$DXCM · $73.37 · as of 2026-07-27 · multi-factor read
67
/ 100
Buy

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$72.00 ↑
100-day$67.86 ↑
200-day$67.54 ↑
Bullish (50 > 200)

RSI (14)

Reading51.6 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateWeakening
Histogram-0.385

Weakening — MACD slipped below its signal line. Histogram expanding.

Bollinger Bands (20,2)

%B / Width53% · 14.8%

Mid-band — no directional band edge in play.

Volume · Buyer vs Seller

Up/Down vol1.14 · Neutral
Rel volume0.89×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $74.92swing level
R · $75.97swing level
R · $79.03swing level
Price · $73.37now
S · $67.30swing level
S · $65.19swing level
S · $63.82swing level

Fibonacci · Uptrend swing

23.6% ◄ price here$73.86
38.2%$70.58
50.0%$67.94
61.8%$65.29
78.6%$61.52

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for DXCM — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishRS 13 (laggard)
Want this read in a legend's voice? 💬 Ask a Legend about DXCM
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini B

Trend-template read: 9/12 pass; wait for the soft misses to improve.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $73.37, MA150 $68.69, MA200 $67.54
1.2 150-day MA > 200-day MAMA150 $68.69 vs MA200 $67.54
Failing evidence
1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 13
2. Quarterly EPS growth ≥ 25%+24.4% QoQ
9/12 checks
Avoid
O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence
A: Annual earnings & revenue qualityRev +15.6% | ROE 33.8%
S: Base tightness (ATR% ≤ 4.5%)ATR% 3.81%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%+24.4% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 13
2/8 checks
Watch
Weinstein C

Stage-analysis read: Stage 2 is present; 3 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $73.37 vs MA200 $67.54
Failing evidence
Volume expansion above averageVolume ratio 0.89x
Relative strength ≥ 60RS 13
4/7 checks
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$73.37
Distance from 52-week high18.5% below high
Failing evidence
Relative strengthRS 13
Volume vs average0.89x
3/6 checks
Watch
Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$73.37
Distance from 52-week high18.5% below high
Failing evidence
Relative strengthRS 13
Volume vs average0.89x
3/6 checks
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence
Price$73.37
Distance from 52-week high18.5% below high
Failing evidence
Relative strengthRS 13
Volume vs average0.89x
3/6 checks
Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
71RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net -2 A+
A: 15 D: 17 Net: -265 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini SEPA criteria · 4/7 met
B 4/7 SEPA
Separate score from the 8-point Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ +24%
Revenue growth ≥20% YoY +16%
Gross margin ≥30% 63%
ROE ≥17% 34%
RS rating ≥80 (leadership) 13
Stage 2 uptrend (Weinstein) Stage 2
Within 25% of 52W high -18.5%

Method Playbook

📋 Trade it like O'Neil EXACT LEVELS · PRO
Minervini O'Neil Livermore Weinstein Darvas Wyckoff
O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.
Pivot
Pro level
Published-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Wyckoff SOS ⚠ Volatility widening into breakout ⚠ 3rd-stage base
49.1 score
RS Score 13
Trend 7/8
CANSLIM 62.4* (C)
range low: 59.937 range high: 73.163 range pct: 0.221 sos thrust: 0.066 sos vol ratio: 1.288 sos bars ago: 7 near lps: ✓ validation reason: valid generic setup multi tf evaluated: ✓ multi tf reason: weekly: MA stabilizing or rising — accumulation context supported
Why This Setup?
Wyckoff SOS

SOS: breakout above range_high=73.16, thrust=6.6%, vol=1.3x avg, lps=near, 7 bars ago | Strong trend (7/8) | High-confidence pattern (78%) | Stage 2 | Readiness 68/100 (watch) | CANSLIM 62.4 (C) | ⚠ Volatility widening into breakout; 3rd-stage base

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

1/7 universals met
Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $73.37 vs SMA150 $68.69 / SMA200 $67.54
SMA 150 above SMA 200 SMA150 $68.69 vs SMA200 $67.54
SMA 200 trending up Slope +0.27 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $72.00
Price above SMA 50 $73.37 vs SMA50 $72.00
30%+ above 52W low +35.6% from $54.11
Within 25% of 52W high -18.5% from $89.98
RS score above 70 RS 13

Fundamentals

52W Range
54%
Mkt Cap SEC
28.3B
EPS QoQ
+24%
Rev YoY
+16%
ROE
34%
Gross Margin
63%
D/E
0.47
EPS TTM
$2.09
P/E TTM
35.1x
Float
386M
Insider
No Buy

Company

Legend AI snapshot
DexCom, Inc.
DXCM · NASDAQ · Health Technology · Medical Specialties
$73.37latest close $28.3Bmarket cap 11RS rank 49setup score
O'Neil · Grade Card
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
C 62.4* CANSLIM * disqualified on C, M
C · Curr. EPS
92
A · Annual EPS
88
N · New Highs
40
S · Supply/Demand
80
L · Leader RS
13
I · Inst. Spons.
100
M · Market
30

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
6/8
W. RS
57
W. Support
$56.72
W. Resist
$79.15
Weekly Structure

Scan History

13× streak
Jul 22: 61 (Trend Only)Jul 23: 49 (Trend Only)Jul 27: 0 (watchlist_candidate)Jul 28: 49 (Wyckoff SOS)Jul 28: 49 (Wyckoff SOS)49
Jul 28
Wyckoff SOS ✓ Gate
49
Jul 28
Wyckoff SOS ✓ Gate
49
Jul 27
watchlist_candidate
0 0.0%
Jul 23
Trend Only ✓ Gate
49 +4.1%
Jul 22
Trend Only ✓ Gate
61 +2.7%

Get the full picture on DXCM

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial